Core Insights - Maiwei Biotech has received approval from the National Medical Products Administration for the Phase II clinical trial application of 9MW3811 injection for pathological scars, potentially becoming the first IL-11 targeted drug to enter clinical stages for this indication [1] Group 1: Clinical Development - The Phase II clinical trial for 9MW3811 is planned to start by the end of 2025, marking a significant milestone in the treatment of pathological scars [1] - 9MW3811 has already been approved for clinical research in advanced malignant tumors and idiopathic pulmonary fibrosis globally, having completed Phase I trials in Australia and China [1] Group 2: Licensing Agreement - The company has entered into an exclusive licensing agreement with CALICO Life Sciences LLC, granting CALICO global rights outside of Greater China [1] - CALICO has made an upfront payment of $25 million to the company, with potential milestone payments reaching up to $571 million related to near-term, development, registration, and commercialization [1]

Core Insights - The company, Maiwei Biotech, has received approval from the National Medical Products Administration for a Phase II clinical trial of its drug 9MW3811 injection for the indication of pathological scars [1] - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, which has already been approved for clinical research in advanced malignancies and idiopathic pulmonary fibrosis globally [1] - The company plans to initiate the Phase II clinical trial for pathological scars by the end of 2025 [1] - Maiwei Biotech has entered into an exclusive licensing agreement with CALICO, receiving an upfront payment of $25 million, with potential milestone payments totaling up to $571 million and royalties [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of 9MW3811 injection for pathological scars, marking a significant advancement in its clinical research pipeline [1] Group 1: Clinical Trial Approval - The company announced that it has obtained the Clinical Trial Approval Notice for 9MW3811 injection for the indication of pathological scars, allowing it to proceed with Phase II clinical trials [1] - The Phase II clinical trial is planned to start by the end of 2025, making it the first IL-11 targeted drug to enter clinical stages for this indication [1] Group 2: Global Research Progress - 9MW3811 has already been approved for clinical research in advanced malignant tumors and idiopathic pulmonary fibrosis globally, having completed Phase I trials in Australia and China [1] - The development progress of 9MW3811 is currently leading among global peers targeting similar pathways [1] Group 3: Licensing Agreement - The company has entered into an exclusive licensing agreement with CALICO Life Sciences LLC, granting CALICO global rights outside of Greater China [1] - CALICO has made an upfront payment of $25 million to the company, with potential milestone payments reaching up to $571 million for near-term, development, registration, and commercialization milestones [1]

Core Viewpoint - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for its clinical trial application for 9MW3811 injection, aimed at treating pathological scars in a Phase II clinical trial [1] Group 1 - The company announced the approval of its clinical trial for 9MW3811 injection [1] - The indication for the clinical trial is pathological scars [1] - The approval is specifically for a Phase II clinical trial [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of 9MW3811 injection for pathological scar indications, marking a significant advancement in its research and development pipeline [1] Group 1: Clinical Trial Approval - The company announced that it has obtained the Clinical Trial Approval Notice for 9MW3811 injection, which is intended for use in pathological scar indications [1] - The II phase clinical trial for 9MW3811 is planned to start by the end of 2025, making it the first IL-11 targeted drug to enter clinical stages in this indication area [1] Group 2: Global Research and Development Progress - 9MW3811 has already been approved for clinical research in advanced malignant tumors and idiopathic pulmonary fibrosis globally, having completed Phase I trials in Australia and China [1] - The development progress of 9MW3811 is currently leading among global peers targeting similar pathways [1] Group 3: Licensing Agreement - The company has entered into an exclusive licensing agreement with CALICO Life Sciences LLC, granting CALICO global rights outside Greater China [1] - CALICO has made an upfront payment of $25 million to the company, with potential milestone payments reaching up to $571 million for near-term, development, registration, and commercialization milestones [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the Phase II clinical trial of its drug 9MW3811, aimed at treating pathological scars [1] Company Summary - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, classified as a Class 1 therapeutic biological product with independent intellectual property rights [1] - The drug effectively inhibits the abnormal activation of the IL-11/IL-11Rα signaling pathway, which is crucial in the progression of fibrotic diseases [1] - Key advantages of 9MW3811 include higher target affinity and signaling blockade capability, as well as a long half-life of over one month, making it suitable for chronic disease treatment requiring long-term administration [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its drug 9MW3811, targeting pathological scars in a Phase II study [1] Company Summary - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, classified as a Class 1 therapeutic biological product with independent intellectual property rights [1] - The drug effectively inhibits the abnormal activation of the IL-11/IL-11Rα signaling pathway, which is crucial in the progression of fibrotic diseases [1] - Key advantages of 9MW3811 include higher target affinity and signaling blockade capability, along with a long half-life of over one month, making it suitable for chronic disease treatment requiring long-term administration [1]

Group 1 - The core point of the news is that Maiwei Biotech's stock price has dropped by 5.01%, currently trading at 42.24 CNY per share, with a total market capitalization of 16.879 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, focuses on the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 256 million CNY, with a turnover rate of 2.90% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) has entered the top ten circulating shareholders of Maiwei Biotech, holding 2.1906 million shares, which is 1.07% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF today is approximately 4.885 million CNY [2] - The Southern CSI 1000 ETF was established on September 29, 2016, with a current scale of 76.63 billion CNY and has achieved a year-to-date return of 28.25% [2] Group 3 - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 7 years and 2 days, managing a total asset scale of 122.76 billion CNY [3] - During Cui Lei's tenure, the best fund return was 176.39%, while the worst return was -15.93% [3]

Group 1 - The core viewpoint of the news is that Maiwei Biotech has shown significant financial activity, with a notable increase in revenue and changes in shareholder structure [1][2]. Group 2 - As of November 6, 2023, Maiwei Biotech's stock price increased by 0.50%, with a trading volume of 304 million yuan. The financing buy-in amount was 22.19 million yuan, while the financing repayment was 30.38 million yuan, resulting in a net financing buy of -8.19 million yuan [1]. - The total margin balance for Maiwei Biotech reached 613 million yuan, with the financing balance accounting for 6.74% of the circulating market value, indicating a high level compared to the past year [1]. - The company has not engaged in any short selling on November 6, 2023, with a short selling balance of 93.38 million yuan, also reflecting a high level compared to the past year [1]. Group 3 - For the period from January to September 2025, Maiwei Biotech reported a revenue of 566 million yuan, representing a year-on-year growth of 301.03%. However, the net profit attributable to the parent company was -598 million yuan, showing a year-on-year increase of 13.89% [2]. - As of September 30, 2025, the number of shareholders for Maiwei Biotech reached 19,600, an increase of 9.15% from the previous period. The average circulating shares per person decreased by 8.38% to 10,425 shares [2]. - Among the top ten circulating shareholders, E Fund Medical Healthcare Industry Mixed A ranked as the fourth largest shareholder with 3.17 million shares, while Hong Kong Central Clearing Limited ranked sixth with 2.87 million shares, showing a decrease of 1.87 million shares from the previous period [2].

Summary of the Conference Call for Maiwei Biotech Company Overview - **Company**: Maiwei Biotech - **Date**: November 4, 2025 Key Points Financial Performance - As of September 30, the company reported cash and cash equivalents of 1.439 billion RMB, an increase of over 200 million RMB compared to the end of last year [5] - Revenue for the first three quarters reached 566 million RMB, a year-on-year increase of 300%, driven by growth in technical service fees and a 70% increase in the sales of Dizu monoclonal antibody [5] - The loss for the third quarter significantly reduced to 49 million RMB, a year-on-year decrease of 200 million RMB, marking the first substantial reduction in losses [5] Business Development (BD) Achievements - The company achieved multiple breakthroughs in BD, including collaborations on Bai Jie 11, small nucleic acids, and long-acting Shengmai injections, resulting in over 800 million RMB in cash inflow [6][7] - Several BD pipelines are in progress, including 94 ADR BTC, CDED, and STE U monoclonal antibodies, with expectations for more results in the future [7] Core Projects and Pipeline Progress - The core pipeline includes 9KT 4 ADC, B713 ADC, and CD17 ADC, with multiple products expected to be approved and initiate patient enrollment in both China and the U.S. [8] - The SE2 monoclonal antibody for COPD has completed enrollment of 80 patients in the EB27 clinical trial, with expectations to complete follow-up by the end of the year [3] - The company is also advancing the CDH17 ADC project, which has received overseas authorization with a total amount exceeding 1 billion USD for liver delivery exploration [3][4] Market Expansion and Product Launches - Dizu monoclonal antibody sales approached 100 million RMB in the first half of the year, ranking first among domestic products [16] - The company has signed agreements with over 10 countries to expand biosimilars into emerging markets, with the first launch in Pakistan in August [16] - A supplemental application for bone metastasis indications is expected to be approved in the first half of next year, which could significantly increase revenue [16] Future Development Plans - The company is focusing on four key platforms: antibody discovery, ADC, TCE, and small nucleic acids, with plans to launch more TCE products into clinical trials next year [8] - The company is also developing treatments for age-related diseases, such as the SE2 monoclonal antibody for COPD, with plans for larger sample size trials [8] Clinical Trials and Regulatory Approvals - The company is actively communicating with the FDA regarding clinical trial designs and endpoints, particularly for the Bai Jie 11 project targeting pathological scars [9][28] - The 2,821 project is expected to focus on single endpoint PFS (Progression-Free Survival) to shorten clinical cycles and sample sizes [18][25] Innovations in Drug Development - The siRNA platform has been authorized to Editas, with ongoing development of dual-target siRNA and exploration of liver and CNS delivery systems [12][33] - The company is also developing a new oral small molecule drug for osteoarthritis, which is currently advancing to phase II clinical trials [14] Market Outlook - The company anticipates significant revenue growth from traditional products like Dizu and Adalimumab, with a complete transition to Maiwei's invoicing by 2026 [22] - The aging population in China is expected to drive demand for ophthalmic preparations, particularly for age-related macular degeneration [38] Conclusion - Maiwei Biotech is positioned for growth with a robust pipeline, significant financial improvements, and strategic collaborations, aiming to expand its market presence and enhance its product offerings in the coming years [39]